Welcome to our dedicated page for Kraig Biocraft Laboratories In SEC filings (Ticker: KBLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monitoring the science and the numbers behind Kraig Biocraft Laboratories is challenging when every breakthrough in recombinant spider silk triggers a new disclosure. Investors first ask, “Where can I find the latest data on production yields or insider funding?” This page guides that journey from curiosity to clarity.
You can jump straight to a Kraig Biocraft Laboratories quarterly earnings report 10-Q filing to track R&D spend, or open the Kraig Biocraft Laboratories annual report 10-K simplified by our AI to see long-term plans for scaling biofactories. Real-time alerts surface each Kraig Biocraft Laboratories 8-K material events explained, so a new government grant or pilot-line expansion never slips past you.
Need visibility into leadership actions? Our dashboard streams Kraig Biocraft Laboratories Form 4 insider transactions real-time, making it easy to spot Kraig Biocraft Laboratories executive stock transactions Form 4 before market chatter begins. Curious about pay packages? One click opens the Kraig Biocraft Laboratories proxy statement executive compensation file, already distilled into plain language.
- AI-powered summaries translate dense genetic terminology—sericin ratios, dragline motifs—into straightforward metrics.
- All filing types, from S-1 to 10-Q, update the moment EDGAR posts.
- Side-by-side comparisons turn raw PDFs into trend charts for revenue, production scale, and dilution risk.
Whether you searched for “Kraig Biocraft Laboratories SEC filings explained simply” or need Kraig Biocraft Laboratories earnings report filing analysis, Stock Titan’s AI keeps the complex story of engineered silk understandable and actionable.
Kraig Biocraft Laboratories (KBLB) reported Q3 results with revenue of $0 and a net loss of $1,509,566 for the quarter; the nine‑month net loss was $2,835,732. Operating expenses were $1,433,888 in Q3 and $2,652,125 year‑to‑date.
As of September 30, 2025, the Company had cash of $1,565,692, a working capital deficiency of $8,544,784, and a stockholders’ deficit of $7,956,077. Management disclosed that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Financing activity included $1,925,702 raised under a Standby Equity Purchase Agreement and common shares issued for services valued at $834,600. The Company sold 111 ounces of gold year‑to‑date for $369,992 in proceeds, recognizing a $160,896 realized gain; remaining gold was carried at $494,478. Related‑party note payable was $1,567,000 with $426,589 in year‑to‑date interest expense. Accounts payable and accrued expenses – related party were $8,004,099. Class A shares outstanding were 1,080,852,130 as of November 12, 2025; 1,076,244,777 were outstanding as of September 30, 2025.
FAQ
What is the current stock price of Kraig Biocraft Laboratories In (KBLB)?
What is the market cap of Kraig Biocraft Laboratories In (KBLB)?
